Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID‐19 trial of nirmatrelvir

…, S Pawlak, EP Kadar, F Clark, H Shi… - Clinical …, 2022 - Wiley Online Library
Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF‐07321332…

Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID‐19, in subjects with renal impairment

…, J Navarro, RA Preston, H Shi… - Clinical …, 2022 - Wiley Online Library
Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk of …

[HTML][HTML] Ultrasmall Au and Ag nanoclusters for biomedical applications: a review

J Tang, H Shi, G Ma, L Luo, Z Tang - Frontiers in Bioengineering and …, 2020 - frontiersin.org
Noble metal (eg, Au, Ag, Pt, Pd, and their alloys) nanoclusters (NCs) have emerged as a new
type of functional nanomaterial in nanoscience and nanotechnology. Owing to their unique …

Calculation of embodied energy in Sino-USA trade: 1997–2011

R Yang, R Long, T Yue, H Shi - Energy Policy, 2014 - Elsevier
In order to find efficient trade measures to reduce China׳s energy consumption and to provide
theoretical support for the climate talks between China and America, we investigate the …

Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults

…, Y Thay Cha, RR LaBadie, H Shi… - British Journal of …, 2023 - Wiley Online Library
Aims The objective of this study was to evaluate the effects of a strong cytochrome P450 family
(CYP) 3A4 inhibitor (itraconazole) and inducer (carbamazepine) on the pharmacokinetics …

Population pharmacokinetics of talazoparib in patients with advanced cancer

Y Yu, C Durairaj, H Shi… - The Journal of Clinical …, 2020 - Wiley Online Library
Poly(ADP‐ribose) polymerase (PARP) inhibitors have been developed to treat cancers
associated with somatic BRCA mutations and germline genetic aberrations involved in the DNA …

Novel application of the two‐period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin

…, V Sahasrabudhe, A Vaz, H Shi… - Clinical and …, 2018 - Wiley Online Library
Ertugliflozin, a sodium glucose cotransporter‐2 inhibitor, is approved in the United States for
treatment of type 2 diabetes mellitus. A novel two‐period study design with 14 C microtracer …

Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours

…, CH Chung, A Plotka, H Shi… - British Journal of …, 2020 - Wiley Online Library
Aims In vitro data show that talazoparib is a substrate for P‐glycoprotein (P‐gp) and breast
cancer resistance protein transporters. This open‐label, 2‐arm, drug–drug interaction Phase …

Prenatal diagnosis of skeletal dysplasias using whole exome sequencing in China

J Tang, C Zhou, H Shi, Y Mo, W Tan, T Sun, J Zhu… - Clinica Chimica …, 2020 - Elsevier
Background Skeletal dysplasias account for nearly 10% of fetal structural malformations
detected by ultrasonography. This clinically heterogeneous group of genetic anomaly includes …

[HTML][HTML] Current research progress on long noncoding RNAs associated with hepatocellular carcinoma

H Shi, Y Xu, X Yi, D Fang, X Hou - Analytical Cellular Pathology, 2019 - hindawi.com
Hepatocellular carcinoma (HCC) is the second leading cause of mortality among cancers. It
has been found that long noncoding RNAs (lncRNAs) are involved in many human cancers, …